The scheme, which is effective as of 2014, effectively means that pharmaceutical companies and the government may agree to a price contingent based on the drugs efficacy. For example if a kidney drug from Pfizer proves to be more effective than a kidney drug from GSK, GSK must offer a partial rebate to the NHS.
However, the chairman of NICE Sir Michael Rawlins has said he would prefer the big pharma companies to offer a discount initially rather than resorting to complicated rebates further down the line.
Are you looking for a new position in the pharmaceutical industry? Click here to search our current pharmaceutical jobs online now.